Patrick Schöffski, Date of Birth, Place of Birth
TweetPatrick Schöffski
German oncologist
Date of Birth: 27-Dec-1963
Place of Birth: Hanover, Lower Saxony, Germany
Profession: oncologist
Zodiac Sign: Capricorn 
About Patrick Schöffski
- Patrick Schöffski is a medical doctor specializing in internal medicine, hematology and medical oncology.
- He originates from Hannover, Germany, where he also received a master's degree in public health at Hannover Medical School. He is the head of the Department of General Medical Oncology at the University Hospitals Leuven and also leads the Laboratory of Experimental Oncology at KU Leuven, Belgium.
- He was Secretary-General of the Executive Committee and Board of the European Organisation for Research and Treatment of Cancer (EORTC), part of the Board of Directors of the European Cancer Organisation (ECCO) and the Connective Tissue Oncology Society (CTOS) and is a current member of many scientific societies including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and others.
- In 2013 he was appointed member of the Belgian Royal Academy of Medicine. Schöffski’s main clinical interest is the treatment of solid tumors and lymphomas.
- He is involved in a large number of prospective clinical trials (Phase I-III) in various tumor types, including orphan malignancies.
- He leads an active phase I-team in Leuven, has a strong interest in multitumor phase II-screening studies, runs complex clinical trials in the field of personalized oncology and registration studies in various malignancies.
- He coordinates translational research projects associated with new drug development in diseases such as sarcoma, urogenital and endocrine malignancies, and others.
- He has been involved in pivotal registration trials of antineoplastic agents in a variety of solid tumors with significant activity in rare malignancies.
- Prof.
- Schöffski has a strong background in clinical trial methodology.
- His Laboratory of Experimental Oncology at KU Leuven has a focus on mesenchymal malignancies and developed more than 40 patient-derived xenograft models of soft tissue sarcomas and gastrointestinal stromal tumors since 2004, which are used for early drug screening and cancer biology studies in collaboration with academic groups, biothech and pharmaceutical companies.
- This laboratory work has been the rationale for a number of ongoing and completed clinical trials. He was work package leader in the Connective Tissue Cancers Network (CONTICANET), a Network of Excellence funded by the European Commission’s Sixth Framework Programme.
- He is member of the new EURACAN network for rare malignancies in Europe.
- In 2019 Prof.
- Schöffski founded FORTRESS, the Forum for Translational Research in Sarcomas, an annual meeting for scientists involved in laboratory research in the field of soft tissue and bone sarcoma and gastrointestinal stromal tumors.
- The meeting is organized in collaboration with researchers from KU Leuven and Westdeutsches Tumorzentrum in Essen (Germany) and alternates between Leuven and Essen. Prof.
- Schöffski has published almost 300 papers in international peer-reviewed oncology journals and promoted numerous doctoral and PhD thesis projects.
- He is member of the advisory board of several pharmaceutical and biotech companies and has been an independent advisor to academic organizations such as Cancéropôle Île-de-France, Paris (France), the Ontario Institute for Cancer Research, Toronto (Canada) and the Cancer Center of Helsinki University Central Hospital (Finland).
- Until 2014 he acted as scientific chair of the Methods in Clinical Cancer Research Workshop series in Flims, Switzerland, organized by AACR, ECCO, ESMO and EORTC, and is involved in multiple educational activities in oncology on an international level.
- Based on his methodological and clinical research expertise, Prof.
- Schöffski is member of (or coordinates) a number of Independent Data Monitoring Committees for ongoing and completed Phase II/III clinical trials in collaboration with academic groups, biotech companies, clinical research organizations and pharmaceutical companies.
Read more at Wikipedia